{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:28:14Z","timestamp":1764588494025,"version":"build-2065373602"},"reference-count":85,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: More than 430,000 new cases of renal cell carcinoma (RCC) were reported in 2020. Clear cell RCC, which occurs in 80% of cases, is often associated with mutations in the VHL gene, leading to dysregulation of hypoxia-induced transcription factors pathways and carcinogenesis. The purpose of this study is to examine the adverse events (AEs) of cabozantinib treatment and the relationship between individual patient factors and the frequency of their occurrence in detail. Materials and Methods: Seventy-one patients with metastatic RCC were treated with second or further lines of cabozantinib at the Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology. Comprehensive data, including demographics, clinicopathological factors, and AEs, were collected from January 2017 to June 2021. This study evaluated the impact of various patient-related factors on the rate of adverse events and treatment tolerance using a Cox proportional hazards model. Results: Cabozantinib-induced AEs were significantly associated with body mass index (BMI), body surface area (BSA), IMDC prognostic score, and treatment line. Notably, patients receiving cabozantinib post-tyrosine kinase inhibitors reported fewer AEs. Dose reduction was unrelated to adverse event frequency, but patients requiring dose reduction were characterized with lower body mass and BSA but not BMI. Conclusions: The factors described make it possible to predict the incidence of AEs, which allows for faster detection and easier management, especially in the high-risk group. AEs should be reported in detail in real-world studies, as their occurrence has a significant impact on prognosis.<\/jats:p>","DOI":"10.3390\/medicina60030398","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T07:51:39Z","timestamp":1708933899000},"page":"398","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients\u2014Real-World Experience in a Single-Center Retrospective Study and Narrative Review"],"prefix":"10.3390","volume":"60","author":[{"given":"Piotr","family":"Doma\u0144ski","sequence":"first","affiliation":[{"name":"Department of Experimental Immunotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"},{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6451-1238","authenticated-orcid":false,"given":"Mateusz","family":"Pi\u0119tak","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szymon","family":"Staneta","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weronika","family":"Fortuniak","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5782-7151","authenticated-orcid":false,"given":"Barbara","family":"Kruczyk","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4879-6837","authenticated-orcid":false,"given":"Adam","family":"Kobiernik","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Baku\u0142a","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mydlak","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Demkow","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017cena","family":"Sikora-Kupis","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-857X","authenticated-orcid":false,"given":"Paulina","family":"Dumnicka","sequence":"additional","affiliation":[{"name":"Chair of Biochemistry, Jagiellonian University Medical College, 31-034 Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-8910","authenticated-orcid":false,"given":"Jakub","family":"Kucharz","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology Roentgena 5, 02-781 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref_1","unstructured":"World Cancer Research Fund (2023, December 20). Kidney Cancer Statistics. Available online: https:\/\/www.wcrf.org\/cancer-trends\/kidney-cancer-statistics\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10875","DOI":"10.1038\/s41598-022-14779-6","article-title":"Cancer Incidence and Mortality in Poland in 2019","volume":"12","author":"Didkowska","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ucl.2008.07.006","article-title":"Molecular Biology of Renal Cortical Tumors","volume":"35","author":"Klatte","year":"2008","journal-title":"Urol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/327721a0","article-title":"Loss of Alleles of Loci on the Short Arm of Chromosome 3 in Renal Cell Carcinoma","volume":"327","author":"Zbar","year":"1987","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.eururo.2007.12.001","article-title":"Impact of Gender in Renal Cell Carcinoma: An Analysis of the SEER Database","volume":"54","author":"Aron","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_6","first-page":"167","article-title":"Treatment Options in Localised and Metastatic Renal Cell Carcinoma","volume":"1","author":"Berger","year":"2008","journal-title":"Memo\u2014Mag. Eur. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2020.12.005","article-title":"Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-na\u00efve Metastatic Clear-Cell Renal Cell Carcinoma","volume":"79","author":"Bedke","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab Plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","article-title":"Cabozantinib in Patients with Platinum-Refractory Metastatic Urothelial Carcinoma: An Open-Label, Single-Centre, Phase 2 Trial","volume":"21","author":"Apolo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fonc.2015.00202","article-title":"Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data","volume":"5","author":"Ott","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","article-title":"Dual Effects of a Targeted Small-Molecule Inhibitor (Cabozantinib) on Immune-Mediated Killing of Tumor Cells and Immune Tumor Microenvironment Permissiveness When Combined with a Cancer Vaccine","volume":"12","author":"Kwilas","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jancewicz, I., Szarkowska, J., Konopinski, R., Stachowiak, M., Swiatek, M., Blachnio, K., Kubala, S., Oksinska, P., Cwiek, P., and Rusetska, N. (2021). PD-L1 Overexpression, SWI\/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4(+) T Cells. Cancers, 13.","DOI":"10.3390\/cancers13164148"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1016\/j.clgc.2019.02.002","article-title":"Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program","volume":"17","author":"Bodnar","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12032-017-0928-z","article-title":"Sunitinib-Induced Hypothyroidism Predicts Progression-Free Survival in Metastatic Renal Cell Carcinoma Patients","volume":"34","author":"Kucharz","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/5584_2018_328","article-title":"Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma","volume":"1133","author":"Kucharz","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12032-018-1239-8","article-title":"The Correlation between the Incidence of Adverse Events and Progression-Free Survival in Patients Treated with Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC)","volume":"36","author":"Kucharz","year":"2019","journal-title":"Med. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1532-5415.1987.tb01407.x","article-title":"The Aging Kidney: Structure, Function, Mechanisms, and Therapeutic Implications","volume":"35","author":"Anderson","year":"1987","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic Factors for Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-Targeted Agents: Results from a Large, Multicenter Study","volume":"27","author":"Heng","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_21","unstructured":"Agency, European Medicines (2024, February 21). Summmary of Product Characteristics Cabozantinib. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_en.pdf."},{"key":"ref_22","unstructured":"U.S. Department of Health and Human Services (2024, February 21). Common Terminology Criteria for Adverse Events (Ctcae) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5507\/bp.2020.055","article-title":"Patients with Metastatic Renal Cell Carcinoma Treated with Cabozantinib in the Czech Republic: Analysis of Four Cancer Centers","volume":"166","author":"Richter","year":"2022","journal-title":"Biomed. Pap. Med. Fac. Palacky Univ. Olomouc"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/1078155219875509","article-title":"Cabozantinib Use in Metastatic Renal Cell Carcinoma Patients in Clinical Practice: Evaluation of Dosing Patterns, Tolerability, and Outcomes Compared to Clinical Trials","volume":"26","author":"McElwee","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in Advanced Non-Clear-Cell Renal Cell Carcinoma: A Multicentre, Retrospective, Cohort Study","volume":"20","author":"Xie","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejca.2018.08.014","article-title":"Cabozantinib for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Retrospective Analysis","volume":"104","author":"Campbell","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/COC.0000000000000478","article-title":"Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program","volume":"42","author":"Prisciandaro","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1016\/j.clgc.2018.03.014","article-title":"Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program","volume":"16","author":"Procopio","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cam4.3717","article-title":"Cabozantinib Real-World Effectiveness in the First-Through Fourth-Line Settings for the Treatment of Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"10","author":"Gan","year":"2021","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results from a Randomised, Open-Label, Phase 3 Trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10147-022-02283-w","article-title":"Final Efficacy and Safety Results and Biomarker Analysis of a Phase 2 Study of Cabozantinib in Japanese Patients with Advanced Renal Cell Carcinoma","volume":"28","author":"Nakaigawa","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Iinuma, K., Tomioka-Inagawa, R., Kameyama, K., Taniguchi, T., Kawada, K., Ishida, T., Nagai, S., Enomoto, T., Ueda, S., and Kawase, M. (2022). Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123172"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/oncolo\/oyac158","article-title":"Efficacy of Cabozantinib in Metastatic Mit Family Translocation Renal Cell Carcinomas","volume":"27","author":"Thouvenin","year":"2022","journal-title":"Oncologist"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2022.0238","article-title":"Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the Bonsai Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)","volume":"8","author":"Procopio","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hahn, A.W., Surasi, D.S., Viscuse, P.V., Bathala, T.K., Wiele, A.J., Campbell, M.T., Zurita, A.J., Shah, A.Y., Jonasch, E., and Gao, J. (2023). Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and\/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist, oyad302.","DOI":"10.1093\/oncolo\/oyad302"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"113292","DOI":"10.1016\/j.ejca.2023.113292","article-title":"Efficacy and Safety of Cabozantinib Rechallenge in Metastatic Renal Cell Carcinoma: A Retrospective Multicentric Study","volume":"193","author":"Baudry","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_40","first-page":"73","article-title":"Multicentric Hungarian Results of Cabozantinib Therapy in Patients with Metastatic Kidney Cancer Based on Real-World Data","volume":"67","author":"Balogh","year":"2023","journal-title":"Magy Onkol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11523-021-00828-z","article-title":"Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study","volume":"16","author":"Santoni","year":"2021","journal-title":"Target. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A Comparison of Sunitinib with Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary Renal Cell Carcinoma: A Randomised, Open-Label, Phase 2 Trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101966","DOI":"10.1016\/j.ctrv.2020.101966","article-title":"Optimizing Treatment of Renal Cell Carcinoma with VEGFR-TKIs: A Comparison of Clinical Pharmacology and Drug-Drug Interactions of Anti-Angiogenic Drugs","volume":"84","author":"Fogli","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_44","first-page":"333","article-title":"Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis","volume":"10","author":"Lemke","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Proskorovsky, I., Benedict, A., Negrier, S., Bargo, D., Sandin, R., Ramaswamy, K., Desai, J., Cappelleri, J.C., and Larkin, J. (2018). Axitinib, Cabozantinib, or Everolimus in the Treatment of Prior Sunitinib-Treated Patients with Metastatic Renal Cell Carcinoma: Results of Matching-Adjusted Indirect Comparison Analyses. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5157-0"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14737140.2022.2002688","article-title":"Cabozantinib beyond Progression Improves Survival in Advanced Renal Cell Carcinoma Patients: The CABEYOND Study (Meet-URO 21)","volume":"22","author":"Mennitto","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clgc.2021.09.005","article-title":"Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes","volume":"20","author":"Venugopal","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clgc.2021.11.004","article-title":"Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients","volume":"20","author":"Martini","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/03008916221138881","article-title":"A Multicenter Phase 2 Single Arm Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pre-Treated with One Immune-Checkpoint Inhibitor: The BREAKPOINT Trial (Meet-Uro Trial 03)","volume":"109","author":"Procopio","year":"2023","journal-title":"Tumori"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"TPS370","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS370","article-title":"CONTACT-03: Randomized, Open-Label Phase III Study of Atezolizumab Plus Cabozantinib versus Cabozantinib Monotherapy Following Progression on\/after Immune Checkpoint Inhibitor (ICI) Treatment in Patients with Advanced\/Metastatic Renal Cell Carcinoma","volume":"39","author":"Pal","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"viii317","DOI":"10.1093\/annonc\/mdy283.102","article-title":"893PCabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Data from UK Expanded Access Program (EAP)","volume":"29","author":"Venugopal","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2020.05.009","article-title":"Activity of Cabozantinib after Immune Checkpoint Blockade in Metastatic Clear-Cell Renal Cell Carcinoma","volume":"135","author":"McGregor","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_53","first-page":"190","article-title":"Activity of Cabozantinib in Further Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Real-World Experience in a Single-Center Retrospective Study","volume":"27","author":"Kruczyk","year":"2023","journal-title":"Contemp. Oncol.\/Wsp\u00f3\u0142czesna Onkol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ijc.27639","article-title":"Body Mass Index and Survival in Patients with Renal Cell Carcinoma: A Clinical-Based Cohort and Meta-Analysis","volume":"132","author":"Choi","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10654-015-0088-4","article-title":"Molecular Pathological Epidemiology Gives Clues to Paradoxical Findings","volume":"30","author":"Nishihara","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2015.61.6441","article-title":"Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database","volume":"34","author":"Renfro","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10552-010-9618-2","article-title":"Obesity Is Associated with Improved Survival in Patients with Organ-Confined Clear-Cell Kidney Cancer","volume":"21","author":"Waalkes","year":"2010","journal-title":"Cancer Causes Control."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1464-410X.2009.08706.x","article-title":"Obesity Is Associated with a Higher Risk of Clear-Cell Renal Cell Carcinoma Than with Other Histologies","volume":"105","author":"Lowrance","year":"2010","journal-title":"BJU Int."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Doma\u0144ski, P., Jarosi\u0144ska, J., Kruczyk, B., Pi\u0119tak, M., Mydlak, A., Demkow, T., Kuncman, \u0141., Darewicz, M., Sikora-Kupis, B., and Michalski, W. (2024). Prognostic Value of Pan-Immune-Inflammation Value and Body Mass Index in Geriatric Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors as First Line Treatment. A Single-Center Retrospective Study. Contemp. Oncol.\/Wsp\u00f3\u0142czesna Onkol., 27.","DOI":"10.5114\/wo.2023.134786"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin Toxicity and Efficacy of Sunitinib and Sorafenib in Metastatic Renal Cell Carcinoma: A National Registry-Based Study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","article-title":"Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma","volume":"50","author":"Bono","year":"2011","journal-title":"Acta Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/1759-7714.13488","article-title":"Immunotherapy as Second-Line Treatment and beyond for Non-Small Cell Lung Cancer in a Single Center of China: Outcomes, Toxicities, and Clinical Predictive Factors from a Real-World Retrospective Analysis","volume":"11","author":"Chen","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., and Zhang, F. (2020). Are Immune-Related Adverse Events Associated with the Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer? A Systematic Review and Meta-Analysis. BMC Med., 18.","DOI":"10.1186\/s12916-020-01549-2"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-World Efficacy and Safety of Nivolumab in Previously-Treated Metastatic Renal Cell Carcinoma, and Association between Immune-Related Adverse Events and Survival: The Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Iinuma, K., Enomoto, T., Kawada, K., Fujimoto, S., Ishida, T., Takagi, K., Nagai, S., Ito, H., Kawase, M., and Nakai, C. (2021). Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J. Clin. Med., 10.","DOI":"10.3390\/jcm10225325"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Yano, Y., Ohno, T., Komura, K., Fukuokaya, W., Uchimoto, T., Adachi, T., Hirasawa, Y., Hashimoto, T., Yoshizawa, A., and Yamazaki, S. (2022). Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers, 14.","DOI":"10.3390\/cancers14225659"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"987568","DOI":"10.3389\/fimmu.2022.987568","article-title":"Serological Biomarkers Predict Immune-Related Adverse Events and Clinical Benefit in Patients with Advanced Gastrointestinal Cancers","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.2017.74.7352","article-title":"Cabozantinib, a New Standard of Care for Patients with Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial","volume":"36","author":"Escudier","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1063178","DOI":"10.3389\/fphar.2022.1063178","article-title":"Immune Checkpoint Inhibitors Combined with Tyrosine Kinase Inhibitors or Immunotherapy for Treatment-Naive Metastatic Clear-Cell Renal Cell Carcinoma-A Network Meta-Analysis. Focus on Cabozantinib Combined with Nivolumab","volume":"13","author":"Niewada","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Libertino, J., and Gee, J. (2020). Renal Cancer Contemporary Management: Contemporary Management, Springer.","DOI":"10.1007\/978-3-030-24378-4"},{"key":"ref_73","first-page":"2322","article-title":"Tumor Angiogenesis Modulates Leukocyte-Vessel Wall Interactions In Vivo by Reducing Endothelial Adhesion Molecule Expression","volume":"63","author":"Dirkx","year":"2003","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3892\/ol.2013.1231","article-title":"Serum Levels of Vascular Endothelial Growth Factor Are Increased and Correlate with Malnutrition, Immunosuppression Involving MDSCs and Systemic Inflammation in Patients with Cancer of the Digestive System","volume":"5","author":"Nakamura","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4049\/jimmunol.174.1.215","article-title":"Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation","volume":"174","author":"Dikov","year":"2005","journal-title":"J. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.coi.2005.01.011","article-title":"Breaking Tolerance in Cancer Immunotherapy: Time to ACT","volume":"17","author":"Overwijk","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High CD8+\/Regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.bjc.6604965","article-title":"Influence of Bevacizumab, Sunitinib and Sorafenib as Single Agents or in Combination on the Inhibitory Effects of VEGF on Human Dendritic Cell Differentiation from Monocytes","volume":"100","author":"Alfaro","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","article-title":"Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression","volume":"290","author":"Balan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S564","DOI":"10.1016\/j.annonc.2020.08.790","article-title":"718P A Phase II Study of Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC) Receiving Pazopanib after Previous Checkpoint Inhibitor Treatment","volume":"31","author":"Powles","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2020.38.15_suppl.5060","article-title":"INMUNOSUN-SOGUG Trial: A Prospective Phase II Study to Assess the Efficacy and Safety of Sunitinib as Second-Line (2L) Treatment in Patients (pts) with Metastatic Renal Cell Cancer (RCC) Who Received Immunotherapy-Based Combination Upfront","volume":"38","author":"Grande","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus Cabozantinib for Patients with Advanced Clear Cell Renal Cell Carcinoma Previously Treated with Immunotherapy: An Open-Label, Single-Arm, Phase 2 Study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/398\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:59Z","timestamp":1760105099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/3\/398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["medicina60030398"],"URL":"https:\/\/doi.org\/10.3390\/medicina60030398","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}